In this week’s episode of The Spotlight Roundup, we check in with Fireside Project, the first-ever 24/7 psychedelic peer support line; the State of Oregon forms an advisory board to oversee the implementation of psilocybin use in specialized clinics; and The American Journal of Psychiatry publishes new guidance on how to safety and effectively use Ketamine and Esketamine.
Similar Posts
What If Your Child Asked to Watch You Do Drugs With Matt Zemon
In this episode, David Flores speaks with Matt Zemon, the co-founder of Happy and author of Psychedelic for Everyone. They open up about deeply personal stories about their childhood, with Matt sharing a beautiful story about connecting with his son Cole.
Kevin O’Leary Thinks MindMed, Compass Pathways & atai Will Merge | Is this a Good Idea?
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:
www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Join our Newsletter (scroll to the bottom of the page and sign up):
https://psychedelicspotlight.com/
Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PsycInvestor
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
Back to the potential MindMed, Compass Pathways & atai merger that Kevin O
Leary speculates on…
Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They?
The “Shark Tank” star predicts three of the biggest psychedelic companies will merge into a mega-corporation, but our resident Psychedelic Investor wonders: Should they?
Famed investor Kevin O’Leary made a bold prediction last Tuesday, saying that psychedelic companies MindMed, atai Life Sciences and Compass Pathways will merge. For psychedelic stock investors, this would be a tsunami-sized event that would have ripple effects throughout the industry.
The Shark Tank star made the comments at the inaugural Benzinga Psychedelics Capital Conference in Miami, arguing that the companies “each need another $200 million by the time they get this to medicine.” In other words, as I have written before, the psychedelic medicines industry is heavily capital intensive, and getting multiple drugs from pre-clinical trials through Phase 3 trials and approved by the FDA can cost hundreds of millions of dollars.
Even though these companies are three of the best-financed in the industry — atai (Nasdaq: atai) has $362 million, Compass (Nasdaq: CMPS) has $273 million and MindMed (Nasdaq: MNMD, NEO: MMED) has $133 million — the celebrity investor believes that in order to succeed the companies may have to become one.
Read the entire article here: https://psychedelicspotlight.com/kevin-oleary-predicts-3-biggest-psychedelic-companies-will-merge-atai-mindmed-compass-pathways/
One man claims magic mushrooms healed his lost sense of smell. Read the full story here.
https://whyy.org/segments/could-magic-mushrooms-cure-covid-related-smell-loss/
A new anti-depressant study is out. Read the full study here: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0265928#sec011
#Mindmed #kevinoleary #psychedelicstocks
NEW MindMed MDMA trials, Compass Pathways Patent, Small Pharma DMT Trials Begins | MNMD, CMPS, DMT
NEW MindMed MDMA trials, Compass Pathways Patent, Small Pharma DMT Trials Begins | MNMD, CMPS, DMT
What’s up psychedelic investors! We have been seeing a lot of red in the last few months. Companies like MindMed (MNMD: NASDAQ) (MMED:NEO), Compass Pathways (CMPS: NASDAQ) &Small Pharma ( OTC: DMTTF) ( CVE: DMT) have had huge news in the last week. So in this episode we’ll be covering the major news surrounding these psychedelic stocks!
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #CompassPathways #PsychedelicStocks
Medical Applications of Ketamine & Common Misconceptions with Christi Myers, Flow Integrative
In this episode, Christi provides insight into how ketamine impacts people’s physical and mental health. She goes into the comparison of ketamine’s effects compared to other psychedelics and how Flow Integrative’s patient care is unique.
Rick Doblin Interview: Psychedelics and the Soviets, A “Driver’s License” to take Drugs, Curing PTSD
Donate to MAPS: https://maps.org/about-maps/our-team/
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
In today’s episode of Psychedelic Spotlight Podcast, James Hallifax from The Psychedelic Investor, had the pleasure of interviewing Rick Doblin, founder of MAPS. When it comes to psychedelic research, the questions of whether psychedelics can help with mental health, and the de-stigmatization of psychedelics, Rick Doblin is the certified G.O.A.T.
Can MDMA treat PTSD? Rick Doblin (and the science) says YES!
Should psychedelics be legalized? Rick Doblin (and facts and logic) say YES!
Did MDMA save the world from World War III? Rick Doblin says… okay well probably not. But it may have played a role!
To learn more about MAPS and their clinical trial, visit maps.org
While you are there, if you are feeling generous and want to donate to a good cause, MAPS is a charity.
Links:
MDMA and the Soviets
https://thebulletin.org/2021/12/psychedelics-the-newest-tool-in-nuclear-negotiations/
CBS MDMA for Veterans Interview
https://www.cbsnews.com/news/mdma-ecstasy-psychedelics-treating-veterans-ptsd/
Today Show MDMA for Veterans Interview
https://www.today.com/health/mdma-ptsd-study-veteran-shares-experience-rcna4495
#RickDoblin #MDMA #PSYCHEDELICS
Interview with Ed Prideaux, Journalist at the Perception Restoration Foundation
In this episode, journalist Ed Prideaux discusses Hallucinogen Persisting Perception Disorder and some of the other very real risks involved with psychedelic misuse.